Scleroderma autoantibodies are associated with very specific demographic, clinical, organ system, and survival features. The use of scleroderma autoantibodies may be very helpful in determining the prognosis, as well as monitoring and treatment of scleroderma patients. There are many faces of scleroderma that seem to be closely associated with scleroderma autoantibodies. These antibodies should be used in performing clinical trials and in doing genetic and basic research. Hopefully, these scleroderma antibodies will lead to a better understanding of the pathogenesis of scleroderma.